PMID- 31066613
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 35
IP  - 6
DP  - 2019 Jul/Aug
TI  - Fluoroquinolone Antibiotic Prophylaxis to Prevent Post-Traumatic Bacterial 
      Infectious Endophthalmitis: Using Monte Carlo Simulation to Evaluate the 
      Probability of Success.
PG  - 366-371
LID - 10.1089/jop.2019.0013 [doi]
AB  - Purpose: Patients with open globe injuries routinely receive fluoroquinolone (FQ) 
      prophylaxis to prevent bacterial infectious endophthalmitis. Owing to the rarity 
      of this infection, there is an absence of clinical trials evaluating optimal 
      prophylactic FQ dosing. To address this knowledge gap, we conducted a Monte Carlo 
      simulation (MCS)-based study to identify the FQ dosing option(s) that optimize 
      pharmacokinetic-pharmacodynamic FQ target attainment against common bacterial 
      pathogens implicated in post-traumatic bacterial infectious endophthalmitis 
      (PTBIE). Methods: Weighted mean pharmacokinetic parameters and standard 
      deviations for ciprofloxacin, levofloxacin, and moxifloxacin were calculated from 
      published studies in healthy volunteers. The incidence and FQ susceptibility 
      profiles for the most common bacteria causing PTBIE were extracted from the 
      literature. MCS was used to determine the cumulative fraction of response (CFR) 
      for 5 FQ dosing options to determine the probability of attaining 
      pathogen-specific target 24-hour area under the curve to minimum inhibitory 
      concentration ratios in the vitreous humor of the eye against the 4 most common 
      causative bacteria seen in PTBIE. Results: Moxifloxacin 400 mg po daily (M400) 
      achieved the highest CFR (72%). Levofloxacin dosing options achieved CFRs between 
      54% and 63%. Ciprofloxacin dosing options achieved CFRs between 28% and 35%. 
      Conclusion: M400 optimized the likelihood of prophylactic success in the 
      prevention of PTBIE, and based on the study findings, M400 is predicted to 
      optimize the probability of success compared with ciprofloxacin and levofloxacin 
      dosing options currently endorsed by expert opinion.
FAU - Peragine, Christine
AU  - Peragine C
AD  - 1Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada.
AD  - 2Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
FAU - Walker, Sandra A N
AU  - Walker SAN
AD  - 1Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada.
AD  - 2Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
FAU - Walker, Scott
AU  - Walker S
AD  - 1Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada.
AD  - 2Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada.
FAU - Palmay, Lesley
AU  - Palmay L
AD  - 1Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada.
AD  - 3Faculty of Pharmacy, University of Waterloo, Waterloo, Canada.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20190508
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Anti-Bacterial Agents)
RN  - 5E8K9I0O4U (Ciprofloxacin)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - U188XYD42P (Moxifloxacin)
SB  - IM
MH  - Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/pharmacology
MH  - Antibiotic Prophylaxis/*methods
MH  - Ciprofloxacin/administration & dosage/pharmacokinetics/pharmacology
MH  - Databases, Factual
MH  - Dose-Response Relationship, Drug
MH  - Endophthalmitis/microbiology/*prevention & control
MH  - Eye Infections, Bacterial/microbiology/*prevention & control
MH  - Eye Injuries, Penetrating/complications/drug therapy
MH  - Humans
MH  - Levofloxacin/administration & dosage/pharmacokinetics/pharmacology
MH  - Microbial Sensitivity Tests
MH  - Models, Biological
MH  - Monte Carlo Method
MH  - Moxifloxacin/administration & dosage/pharmacokinetics/pharmacology
MH  - Probability
OTO - NOTNLM
OT  - Monte Carlo simulation
OT  - fluoroquinolone
OT  - post-traumatic bacterial endophthalmitis
OT  - prophylaxis
EDAT- 2019/05/09 06:00
MHDA- 2020/06/18 06:00
CRDT- 2019/05/09 06:00
PHST- 2019/05/09 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2019/05/09 06:00 [entrez]
AID - 10.1089/jop.2019.0013 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2019 Jul/Aug;35(6):366-371. doi: 10.1089/jop.2019.0013. 
      Epub 2019 May 8.